Notícias e Atividades da Stemline Therapeutics

Stemline Therapeutics pertence à Menarini Group. Menarini Group tem presença direta em 4 países.

Menarini Group possui 3 subsidiárias incluindo Berlin Chemie, Menarini APAC e Stemline Therapeutics.

Eles estão dentro:

• Farmacêutica75%
• Biotecnologia25%

Veja o organograma con seus 8 executivos principais

Biografias mais buscadas da Stemline Therapeutics

• Ivan Bergstein, Director, Chief Executive Officer and President
• David Gionco, Senior Vice President of Finance and Chief Accountin...
• Ken Hoberman, Chief Operating Officer

Criar um alerta
para seguir os movimentos de executivos da Stemline Therapeutics.

Menarini Group possui 2.350 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Johnson & Johnson Innovative Medicine DIA (Estados Unidos).

Popular M&A news in Biotecnologia

• Transcarent and Accolade have merged  (publicado em 9 de abril de 2025)..
• Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
• Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Kristina Burow - Director da Scholar Rock
• Steven Gillis - Chairman of the Board da VBI Vaccines
• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Stemline Therapeutics

• RSS News Feeds | Stemline Therapeutics
• Menarini Group Completes Acquisition of Stemline Therapeutics | Stemline Therapeutics
• Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million | Stemline Therapeutics
• Stemline Therapeutics to Host Conference Call on Fourth Quarter 2019 Financial Results on March 16, 2020 | Stemline Therapeutics
• Stemline Therapeutics Reports Fourth Quarter 2019 Financial Results | Stemline Therapeutics
• Stemline Therapeutics to Present at the Cowen 40th Annual Health Care Conference | Stemline Therapeutics
• Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS® (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers | Stemline Therapeutics
• Stemline Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference | Stemline Therapeutics
• Stemline Therapeutics Recaps ELZONRIS Clinical Data Presentations in Patients with Myelofibrosis (oral presentation) and Multiple Myeloma at the 61st American Society of Hematology (ASH) Annual Meeting | Stemline Therapeutics
• Stemline Therapeutics Names Robert M. Francomano Chief Commercial Officer | Stemline Therapeutics
• View more press releases Close

Redes sociais sobre Stemline Therapeutics

• Stemline Therapeutics na Wikipedia, Google News e Yahoo Finance
• Stemline Therapeutics na LinkedIn, Twitter e YouTube